PDF(Sci-hub)
Abstract：
Collagen cross-linking (CXL) with ultraviolet light-activated riboflavin is a corneal surface procedure developed for the treatment of keratoconus and corneal ectasia. With the known microbicidal and corneal stiffening effects of ultraviolet irradiation and photoactivated riboflavin, it has recently been introduced for the management of infectious keratitis, especially for ulcers resistant to antimicrobial therapy or associated with corneal melting. Various authors have attempted to use CXL as an adjunctive, salvage or even as the sole treatment for infectious corneal ulcers. The aim of this review was to provide a summary of the clinical studies in the literature. It is worth noting that there is still no consensus on the treatment protocol of CXL against infectious keratitis. The disparities in outcome measures, treatment protocol and study design can confound the interpretation and hamper the generalization of the study results. Based on current evidence, the role of CXL in infectious keratitis remained unclear despite the reported success in some clinical cases. Further investigations are warranted concerning the efficacy and safety of treating infectious keratitis with CXL.
摘要：
胶原蛋白交联（CXL）与紫外线激活的核黄素是一种角膜表面方法，用于治疗圆锥角膜和角膜扩张症。具有已知的紫外线照射和光活化核黄素的杀微生物和角膜硬化作用，它最近被引入用于感染性角膜炎的管理，特别是对于抗微生物治疗或与角膜融化相关的溃疡。各种作者都试图使用CXL作为辅助，挽救甚至作为感染性角膜溃疡的唯一治疗方法。这篇综述的目的是对文献中的临床研究进行总结。值得注意的是,目前对于CXL治疗感染性角膜炎的方案尚无共识。结果衡量标准的差异，治疗方案和研究设计会混淆解释，并妨碍研究结果的推广。根据目前的证据,尽管据报道在一些临床病例中取得了成功,但CXL在感染性角膜炎中的作用仍不清楚.需要进一步研究CXL治疗感染性角膜炎的疗效和安全性。
